Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Seeking Alpha
Mark Goldsmith - CEO, President & Chairman Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So good morning. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim. And it's my great pleasure to welcome Mark Goldsmith, President and CEO of Revolution Medicines. Mark, welcome. Thanks for joining us. Mark Goldsmith CEO, President & Chairman Thanks for having us. Michael Schmidt Guggenheim Securities, LLC, Research Division I'm just going to jump right into questions unless you want to provide a quick overview of the story? Mark Goldsmith CEO, President & Chairman Let's do it. Question-and-Answer Session Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So daraxonrasib, obviously, there's been a lot of focus on the upcoming phase. The first randomized Phase III data to read out, you guid
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026GlobeNewswire
- MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective InhibitorGlobeNewswire
- Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 2/10/26 - Form 4
- 2/10/26 - Form SCHEDULE
- 2/9/26 - Form SCHEDULE
- RVMD's page on the SEC website